Insulin-like growth factor-I in growth and metabolism

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 1-2, 2010, Pages 3-16

  Backeljauw, P ^a   Bang, P ^b   Dunger, D B ^c   Juul, A ^d   Le Bouc, Y ^e   Rosenfeld, R ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Mental Health Center Glostrup   (Denmark)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f STANFORD UNIVERSITY   (United States)

Author keywords

Growth; Igf i deficiency; Insulin like growth factor i; Metabolism; Severe insulin resistance

Indexed keywords

ANDROGEN; ESTROGEN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STAT1 PROTEIN; THYROXINE;

CARBOHYDRATE METABOLISM; DIAGNOSTIC PROCEDURE; GLUCONEOGENESIS; GLYCEMIC CONTROL; GROWTH DISORDER; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HYPOGLYCEMIA; IDIOPATHIC DISEASE; INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LARON SYNDROME; LEPRECHAUNISM; PATIENT IDENTIFICATION; PRIMARY INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REFERENCE VALUE; REVIEW; SHORT STATURE;

EID: 77950847020     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2010.23.1-2.3     Document Type: Review

References (75)

1. Rosenfeld RG. Biochemical diagnostic strategies in the evaluation of short stature: the diagnosis of insulin-like growth factor deficiency. Horm Res 1996; 46: 170-173.
2. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormonea new inborn error of metabolism? Isr J Med Sci 1966; 2: 152-155.
3. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-1261.
4. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121: 641-646.
5. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome.J Pediatr Endocrinol Metab 1995; 8: 149-158.
6. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab. 1997; 82: 629-633. (Pubitemid 27068641)
7. Ranke MB, Savage MO, Châtelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128-134.
8. Backeljauw PF, Underwood LE. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001 ; 86: 1504-1510.
9. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902-910. (Pubitemid 46465661)
10. Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006; 2:436-446. (Pubitemid 44214066)
11. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15:80-101. (Pubitemid 24058597)
12. Ranke MB, Feldt-Rasmussen U, Bang P, Baxter RC, Camacho-Hübner C, Clemmons DR, Juul A, Orskov H, Strasburger CJ. How should insulin-like growth factor I be measured? A consensus statement. Horm Res 20.01; 55 (Suppl 2): 106-109.
13. Frystyk J. Free insulin-like growth factors - measurements and relationship to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004; 14: 337-375. (Pubitemid 39185988)
14. Frystyk J. Utility of free IGF-I measurements. Pituitary 2007; 10: 181-187.
15. Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Müller J, Skakkebaek NE. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 2497-2502. (Pubitemid 27337863)
16. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002; 110: 771-781.
17. Bang P, Baxter RC, Blum WF, Breier BH, Clemmons DR, Hall K, Hintz RL, Holly JM, Rosenfeld RG, Zapf J. Valid measurements of total IGF concentrations in biological fluids. Recommendations from the 3"1 International Symposium on Insulin-like Growth Factors. J Endocrinol 1994; 143: C1-2.
18. Clemmons DR. IGF-I assays: current assay methodo- logies and their limitations. Pituitary 2007; 10:121-128.
19. Juul A, Møller S, Mosfeldt-Laursen E, Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J, Rasmussen, S, Müller J, Henriksen J, Skakkebaek NE. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. J Clin Endocrinol Metab 1998; 83:4408-4415. (Pubitemid 29100144)
20. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993; 76: 1610-1616. (Pubitemid 23164387)
21. Geländer L, Blum WF, Larsson L, Rosberg S, Albertsson-Wikland K. Monthly measurements of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in healthy prepubertal children: characterization and relationship with growth: the 1-year growth study. Pediatr Res 1999; 45: 377-383. (Pubitemid 29157771)
22. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jergensen K, Müller J, Hall K, Skakkebaek NE. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78: 744-752. (Pubitemid 24083322)
23. Juul A, Dalgaard P, Blum WF, Bang, P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-I, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534-2542.
24. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 2004; 89:2271-2274. (Pubitemid 38619863)
25. Baxter RC. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab 1990; 70: 1347-1353. (Pubitemid 20159071)
26. Woods KA, Dastot F, Preece MA, Clark AJ, PostelVinay MC, Châtelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997; 82: 3529-3535. (Pubitemid 27509332)
27. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89: 1031-1044.
28. Rosenfeld RG, Kofoed E, Buckway C, Little B, Woods KA, Tsubaki J, Pratt KA, Bezrodnik L, Jasper H, Tepper A, Heinrich JJ, Hwa V. Identification of the first patient with a confirmed mutation of the JAK-STAT system. Pediatr Nephrol 2005; 20: SOSSOS. (Pubitemid 40309933)
29. Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M, Rosenfeld RG. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 2005; 90: 4260-4266. (Pubitemid 41058207)
30. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulinlike growth factor I gene. N Engl J Med 1996; 335: 1363-1367. (Pubitemid 26360455)
31. Walenkamp MJ, Karperien M, Pereira AM, HilhorstHofstee Y, van Doom J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Wit JM. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005; 90: 2855-2864. (Pubitemid 40686336)
32. Netchine I, Azzi S, Houang M, Seurin D, Perin L, Ricort JM, Daubas C, Legay C, Mester J, Heirich R, Godeau F, Le Bouc Y. Partial primary deficiency of insulin-like growth factor (IGF)-I activity associated with IGFl mutation demonstrates its critical role in growth and brain development. J Clin Endocrinol Metab 2009; 94: 3913-3921.
33. Domeñé HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acidlabile subunit gene. N Engl J Med 2004; 350: 570-577. (Pubitemid 38160787)
34. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006; 91:1826-1831.
35. Bang P, Degerblad M, Thorén M, Schwander J, Blum W, Hall K. Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome. Acta Endocrinol (Copenh) 1993; 128: 397-404.
36. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994; 78: 131-137. (Pubitemid 24026761)
37. Domeñé HM, Scaglia PA, Lteif A, Mahmud FH, Kirmani S, Frystyk J, Bedecarras P, Gutierrez M, Jasper HG. Phenotypic effects of null and haploinsufficiency of acid-labile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab 2007; 92: 4444-4450. (Pubitemid 350074768)
38. van Duyvenvoorde HA, Kempers MJ, Twickler TB, van Doom J, Gerver WJ, Noordam C, Losekoot M, Karperien M, Wit JM, Hermus AR. Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008; 159: 113-120. (Pubitemid 40686336)
39. Fofanova-Gambetti OV, Hwa V, Kirsch S, Pihoker C, Chiu HK, Högler W, Cohen LE, Jacobsen C, Derr MA, Rosenfeld RG. Three novel IGFALS gene mutations resulting in total ALS and severe circulating IGF-I/IGFBP-3 deficiency in children of different ethnic origins. Horm Res 2009; 71: 100-110.
40. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfäffle R, Raile K, Seidel B, Smith RJ, Chemausek SD. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349:2211-2222. (Pubitemid 37485137)
41. Walenkamp MJ, de Muinck Keizer-Schrama SM, de Mos M, KaIfME, van Duyvenvoorde HA, Boot AM, Kant SG, White SJ, Losekoot M, Den Dünnen JT, Karperien M, Wit JM. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin-like growth factor-I receptor due to a terminal 15q26.2->qter deletion detected by multiplex ligation probe amplification. J Clin Endocrinol Metab 2008; 93: 2421-2425. (Pubitemid 351831568)
42. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts CT Jr, Hwa V, Rosenfeld RG. Familial short stature caused by haploinsufficiency of the insulin-like growth factor I receptor due to nonsense-mediated messenger ribonucleic acid decay. J Clin Endocrinol Metab 2009; 94: 1740-1747.
43. Walenkamp MJ, Wit JM. Genetic disorders in the GH IGF-I axis in mouse and man. Eur J Endocrinol 2007; 157 (Suppl 1):S 15-26.
44. Rosenbloom AL, Guevara-Aguirre J. Controversy in clinical endocrinology: Reclassification of insulinlike growth factor I production and action disorders. J Clin Endocrinol Metab 2006; 91:4232-4234. (Pubitemid 44833389)
45. Cohen P. Controversy in clinical endocrinology: Problems with reclassification of insulin-like growth factor I production and action disorders. J Clin Endocrinol Metab 2006; 91:4235-4236. (Pubitemid 44833390)
46. Walenkamp MJ, Wit JM. Single gene mutations causing SGA. Best Pract Res Clin Endocrinol Metab 2008; 22: 433-446.
47. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chemausek SD, Savage MO, Wit JM. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93: 42104217. (Pubitemid 352806728)
48. Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, Chatelain PG, Preece MA, Rosenfeld RG. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993; 77: 14651471. (Pubitemid 24000897)
49. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 2001; 86: 5176-5183. (Pubitemid 33070233)
50. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 15: 369-390. (Pubitemid 24180794)
51. Walenkamp MJ, Wit JM. Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res 2006; 66: 221-230. (Pubitemid 44597720)
52. Kamp GA, Zwinderman AH, Van Doom J, Hackeng W, Frölich M, Schönau E, Wit JM. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol (Oxf) 2002; 57: 315-325. (Pubitemid 35013810)
53. Blair JC, Camacho-Hübner C, Miraki Moud F, Rosberg S, Burren C, Lim S, Clayton PE, Bjamason R, Albertsson-Wikland K, Savage MO. Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clin Endocrinol (Oxf) 2004; 60: 163-168; discussion 161-162. (Pubitemid 38200896)
54. Savage MO, Blair JC, Jorge AJ, Street ME, Ranke MB, Camacho-Hübner C. IGFs and IGFBPs in GH insensitivity. Endocr Dev 2005; 9: 100-106.
55. Laron Z, Klinger B, Erster B, Anin S. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988; ii: 1170-1172. (Pubitemid 18267007)
56. th Annual Meeting, June 2008, San Francisco, CA; P2-563.
57. th Annual Meeting, June 2008, San Francisco, CA; P2-564.
58. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulindependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000; 85: 1518-1524. (Pubitemid 32289494)
59. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007;3:302-310. (Pubitemid 46310535)
60. Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, Mandarino L, Kashyap S, Belfort R, DeFronzo RA. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab 2002; 282: E1360-1368.
61. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993; 92: 2249-2256. (Pubitemid 23333530)
62. th Annual Meeting, June 2008, San Francisco, CA; P2-565.
63. Ogilvy-Stuart AL, Soos MA, Hands SJ, Anthony MY, Dünger DB, O'Rahilly S. Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. J Clin Endocrinol Metab 2001; 86:3319-3326. (Pubitemid 32673504)
64. Longo N, Wang Y, Smith SA, Langley SD, DiMeglio LA, Giannella-Neto D. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet 2002; 11: 1465-1475. (Pubitemid 34746547)
65. Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sönksen PH, Dunger DB, Umpleby AM. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 2004; 89:425-432. (Pubitemid 38185880)
66. Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulindependent diabetes mellitus. Metabolism 1998; 47: 1481-1489. (Pubitemid 28565532)
67. Savage MO, Camacho-Hubner C, Dunger DB. Therapeutic applications of the insulin-like growth factors. Growth Horm IGF Res 2004; 14: 301-308. (Pubitemid 38878056)
68. Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 1998; 83: 542-549. (Pubitemid 28496537)
69. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991; 34: 675-679.
70. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y,-Kobayashi M, Akazawa Y, Nomura M, Yoshimasa Y, Kasuga M, Goji K, Nagakali S, Oyasu H, Imura H. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696-705. (Pubitemid 23127160)
71. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycémie control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205-210.
72. Zenobi PD, Glatz Y, Keller A, Graf S, JaeggiGroisman SE, Riesen WF, Schoenle EJ, Froesch ER. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994; 131: 251257. (Pubitemid 24297514)
73. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulinresistant diabetes mellitus. Diabetes Res Clin Pract 1995; 28(Suppl):S185-194.
74. Vestergaard H, Rossen M, Urhammer SA, Muller J, Pedersen O. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol 1997; 136:475-482. (Pubitemid 27239607)
75. Rosenthal S, Cohen P, Clayton P, Backeljauw P, Bang P, Ten S. Treatment perspectives in idiopathic short stature with a focus on IGF-I deficiency. Pediatr Endocrinol Rev 2007; 4 (Suppl 2): 252-271.